speeches & communication

PhRMA Comment on OIG Regulatory Sprint Proposed Rule

graphic of an open envelope with a speech bubble containing an ellipsis near it

The Pharmaceutical Research and Manufacturers of America (PhRMA) is pleased to submit comments on the proposed rule published by the HHS Office of the Inspector General (OIG) concerning safe harbor protections under the Federal Anti-Kickback Statute (AKS) and exceptions to the Civil Monetary Penalty (CMP) law regarding beneficiary inducements for certain coordinated care, value-based, and patient engagement arrangements.

Download the full letter below.